Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Liver Diseases

Free Subscription 07.09.2026 1 AJR Am J Roentgenol 5 Am J Gastroenterol 8 Anticancer Res 1 Biochem Biophys Res Commun 2 BMC Gastroenterol 1 Cancer Res 2 Dig Dis Sci 2 Endoscopy 1 Gut 2 Hepatology 1 Int J Cancer 1 J Gastroenterol 10 J Gastroenterol Hepatol 2 J Hepatol 1 J Pediatr 1 Oncogene 1 PLoS One 1 Radiology 5 Transplant Proc

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

AJR Am J Roentgenol

1. JUNG YJ, Choi SH, Heo S, Kim DH, et al
   Interreader Agreement for Individual Ancillary Features in LI-RADS CT/MRI Version 2018: A Systematic Review and Meta-Analysis.
   AJR Am J Roentgenol. 2026 Apr 22. doi: 10.2214/AJR.26.34591.
   PubMed         Abstract available
   
   

   
   Am J Gastroenterol

2. DEUTSCH-LINK S, Byers IS, Gu H, Arab JP, et al
   Addiction in Gastrointestinal and Liver Disorders.
   Am J Gastroenterol. 2026;121:2121-2131.
   PubMed         Abstract available
   
   
3. SHAIK MR, Rotman Y
   Poor Sensitivity of the Fatty Liver Index Among Lean Individuals.
   Am J Gastroenterol. 2026;121:2231-2241.
   PubMed         Abstract available
   
   
4. VAN HOOFF MC, de Veer RC, Werner E, Beuers U, et al
   Effectiveness and tolerability of bezafibrate in primary biliary cholangitis - a nationwide real-world study.
   Am J Gastroenterol. 2025 Dec 9. doi: 10.14309/ajg.0000000000003879.
   PubMed         Abstract available
   
   
5. VERMA N, Valsan A, Garg P, Sarabu S, et al
   Empirical Antifungal Therapy Improves Survival in Patients With Acute-on-Chronic Liver Failure With Suspected Invasive Fungal Infections: A Pragmatic Randomized Trial.
   Am J Gastroenterol. 2026;121:2198-2210.
   PubMed         Abstract available
   
   
6. BOWLUS CL, Thorburn D, Barclay ST, Joshi D, et al
   Nebokitug, an anti-CCL24 monoclonal antibody, in patients with primary sclerosing cholangitis: A phase 2 study.
   Am J Gastroenterol. 2025 Nov 19. doi: 10.14309/ajg.0000000000003853.
   PubMed         Abstract available
   
   

   
   Anticancer Res

7. YUSA T, Masuda T, Tomiguchi M, Nagayama Y, et al
   A Case of Concurrent Liver Metastases from Colorectal and Breast Cancer Diagnosed Using Percutaneous Tumor Biopsy.
   Anticancer Res. 2026;46:5339-5345.
   PubMed         Abstract available
   
   
8. HORI T, Yamamoto K, Aoi H, Koizumi Y, et al
   Antiproteinuric Effect of SGLT2 Inhibitors in Patients With Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab.
   Anticancer Res. 2026;46:5141-5154.
   PubMed         Abstract available
   
   
9. YUEH TC, Wu MH, Yang MD, Lu MC, et al
   MMP-2 rs243865 Polymorphism as a Risk Modifier of Hepatocellular Carcinoma in Taiwanese Males, Smokers and Alcohol Consumers.
   Anticancer Res. 2026;46:4867-4880.
   PubMed         Abstract available
   
   
10. KUWANO A, Yada M, Tanaka K, Hamamoto T, et al
    Patterns of Response to Durvalumab Plus Tremelimumab and Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.
    Anticancer Res. 2026;46:5217-5227.
    PubMed         Abstract available
    
    
11. TAKAGI K, Nishiyama T, Kimura J, Fuji T, et al
    Impact of Cirrhosis Outcome Risk Estimator (CORE) Risk Score on Prognosis Following Hepatectomy for Hepatocellular Carcinoma.
    Anticancer Res. 2026;46:4993-5001.
    PubMed         Abstract available
    
    
12. OMORI M, Komatsu S, Tada T, Ishihara N, et al
    Early LMR Dynamics and AFP Status in Advanced HCC Treated With Atezolizumab/Bevacizumab.
    Anticancer Res. 2026;46:5119-5127.
    PubMed         Abstract available
    
    
13. IKUTA S, Aihara T, Nakajima T, Iwasaki T, et al
    Repeat Hepatectomy Versus Thermal Ablation for Intrahepatic Recurrence After Resection of Colorectal Liver Metastases: A Propensity-adjusted Analysis With Multiple Imputation.
    Anticancer Res. 2026;46:5281-5287.
    PubMed         Abstract available
    
    
14. KONISHI K, Wakabayashi K, Ikenohira T, Yamashita R, et al
    Lesion-level Quantitative Post-therapy SPECT/CT During (177)Lu-DOTATATE PRRT for NET Liver Metastases.
    Anticancer Res. 2026;46:5301-5309.
    PubMed         Abstract available
    
    

    
    Biochem Biophys Res Commun

15. ZENG M, Guan Q, Guo Y, Cheng H, et al
    Hepatocyte NAT10-mediated ac4C regulation contributes to TGFbeta1-associated Kupffer cell -HSC communication in steatotic liver disease.
    Biochem Biophys Res Commun. 2026;835:154477.
    PubMed         Abstract available
    
    

    
    BMC Gastroenterol

16. NIKPARAST A, Sepehrinia M, Zamanian N, Razaz JM, et al
    Adherence to the dietary index for gut microbiota and the 5-year incidence of metabolic dysfunction-associated steatotic liver disease in Iranian adults: a prospective cohort study.
    BMC Gastroenterol. 2026;26:535.
    PubMed         Abstract available
    
    
17. ZHANG B, Chen X, Zhan Z, Li Y, et al
    The triglyceride to HDL?C ratio explains part of the association between fatty liver and incident type 2 diabetes: a statistical mediation analysis of the NAGALA cohort.
    BMC Gastroenterol. 2026;26:533.
    PubMed         Abstract available
    
    

    
    Cancer Res

18. SHI S, Yan J, Zhang Y, Zhang Y, et al
    Chemotherapy Reawakens Dormant Disseminated Pancreatic Cancer Cells in the Liver by Promoting Senescent Hepatocyte-Induced Neutrophil Extracellular Traps.
    Cancer Res. 2026 Sep 4. doi: 10.1158/0008-5472.CAN-26-0151.
    PubMed         Abstract available
    
    

    
    Dig Dis Sci

19. BOWLER T, Vollmer L, Hubbell A, Aby ES, et al
    Hepatology-Led Education on Alcohol-Related Liver Disease During Chemical Dependency Treatment: Impact on Return to Drinking.
    Dig Dis Sci. 2026 Aug 31. doi: 10.1007/s10620-026-10213.
    PubMed         Abstract available
    
    
20. KIM SM, Wang K, Choi HH, Shui AM, et al
    Longitudinal Adherence to Hepatocellular Carcinoma Surveillance and Associated Outcomes Following Ultrasound Liver Imaging Reporting and Data System (US LI-RADS) Implementation.
    Dig Dis Sci. 2026 Aug 28. doi: 10.1007/s10620-026-10215.
    PubMed         Abstract available
    
    

    
    Endoscopy

21. TAMAI N, Takano Y, Noda J, Azami T, et al
    Occult hepatocellular carcinoma presenting as bile duct invasion: A case diagnosed by cholangioscopy.
    Endoscopy. 2026 Aug 31. doi: 10.1055/a-2930-8982.
    PubMed        
    
    
22. OZAWA E, Takahashi K, Imamura H, Adachi T, et al
    Direct fluoroscopic evidence of preserved side-branch drainage with a multi-hole covered metal stent for benign hepaticojejunostomy stricture after pancreaticoduodenectomy.
    Endoscopy. 2026 Aug 31. doi: 10.1055/a-2936-2633.
    PubMed        
    
    

    
    Gut

23. KONINGS B, Balsiger LM, Tack J
    Response to: Beyond gastrointestinal symptom burden: exploring the impact of previous cholecystectomy on ultrasound-based hepatocellular carcinoma surveillance in patients with liver cirrhosis.
    Gut. 2026 Sep 4:gutjnl-2026-340428. doi: 10.1136/gutjnl-2026-340428.
    PubMed        
    
    

    
    Hepatology

24. WANG H, Zhang S, Zhang C, Liu H, et al
    Genetic regulation of CPEB3-mediated alternative polyadenylation associated with survival of patients with hepatocellular carcinoma.
    Hepatology. 2026 Sep 1. doi: 10.1097/HEP.0000000000001859.
    PubMed         Abstract available
    
    
25. SERPER M, Kosinski A, Navarro V, Kalman R, et al
    Telehealth versus in-person early palliative care for patients with cirrhosis: An ancillary study from the multi-center PAL-LIVER trial.
    Hepatology. 2026 Sep 2. doi: 10.1097/HEP.0000000000001860.
    PubMed        
    
    

    
    Int J Cancer

26. LEE J, Kim HJ, Park SJ, Park S, et al
    Tibolone Use Associated With Elevated Hepatocellular Carcinoma Risk: Findings From a Nationwide Cohort.
    Int J Cancer. 2026 Sep 1. doi: 10.1002/ijc.70725.
    PubMed         Abstract available
    
    

    
    J Gastroenterol

27. SUZUKI T, Matsuura K, Hashimoto Y, Okina M, et al
    B cell receptor-associated protein 31 levels in serum-derived extracellular vesicles are associated with therapeutic response and prognosis in patients with advanced hepatocellular carcinoma receiving atezolizumab plus bevacizumab: a multicenter study
    J Gastroenterol. 2026 Sep 4. doi: 10.1007/s00535-026-02515.
    PubMed         Abstract available
    
    

    
    J Gastroenterol Hepatol

28. BHAWISH R, Ansar S
    Comment on "Smoking and Risk of Hepatic Steatosis Within the MASLD Spectrum in Korean Young Adults".
    J Gastroenterol Hepatol. 2026 Sep 3. doi: 10.1111/jgh.70721.
    PubMed        
    
    
29. ALKUWAITI MA, Al-Harbi FA, Alsaif AK, AlSughayyir ZM, et al
    GLP-1 RA Plus SGLT2i Versus Monotherapy in MASLD and Type 2 Diabetes: Three Pairwise Target Trial Emulations.
    J Gastroenterol Hepatol. 2026;41:2862-2881.
    PubMed         Abstract available
    
    
30. CHOWDHARY R, Prasad S, Koo TH, Liu BDX, et al
    Burden of Eosinophilic Esophagitis and Gastroesophageal Reflux Disease in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comprehensive US Healthcare Analysis.
    J Gastroenterol Hepatol. 2026 Jul 22. doi: 10.1111/jgh.70609.
    PubMed         Abstract available
    
    
31. SOGABE M, Okahisa T, Kagawa M, Shinomiya R, et al
    Comparing the Effect of Changes in Alcohol Intake on Liver Fibrosis Risk Scores Among Patients With Two Distinct Types of Steatotic Liver Disease.
    J Gastroenterol Hepatol. 2026;41:2697-2708.
    PubMed         Abstract available
    
    
32. ZHAO X, Peng S, Zhong K, Wang M, et al
    Macrophage ACAT1 Aggravates Alcohol-Associated Liver Disease by Inducing Mitochondrial Damage and NLRP3 Activation.
    J Gastroenterol Hepatol. 2026;41:2938-2952.
    PubMed         Abstract available
    
    
33. CHON YE, Han KD, Yang JD, Park JY, et al
    Risk of HCC in Elderly Patients With MASLD: Proposal of an Effective Surveillance Strategy.
    J Gastroenterol Hepatol. 2026;41:2913-2924.
    PubMed         Abstract available
    
    
34. GAO F, Zhang Y, Ding Y, Li Y, et al
    Noninvasive Detection of MASH and Fibrotic Burden Using Ultrasound-Derived LIID and LSM in MASLD: A Multicenter Study.
    J Gastroenterol Hepatol. 2026;41:2843-2852.
    PubMed         Abstract available
    
    
35. STRASSER SI, Thompson AJ, Gupta R, Lubel J, et al
    Treatment Goals for Primary Biliary Cholangitis, an Australian Perspective.
    J Gastroenterol Hepatol. 2026 Aug 9. doi: 10.1111/jgh.70616.
    PubMed         Abstract available
    
    
36. WONG VW
    MAFLD/MASLD: Past, Present, and Future.
    J Gastroenterol Hepatol. 2026;41:2882-2892.
    PubMed         Abstract available
    
    
37. LEE A, Han CI, Yang K, Yang H, et al
    Emerging Indices Outperform Traditional Fibrosis Scores in Young Metabolic Dysfunction-Associated Steatotic Liver Disease Across Divergent Screening Goals.
    J Gastroenterol Hepatol. 2026;41:2925-2937.
    PubMed         Abstract available
    
    

    
    J Hepatol

38. IOANNOU GN, Jepsen P, Rowe IA
    Emerging strategies for hepatocellular carcinoma surveillance: abbreviated MRI, biomarkers and benefit stratification.
    J Hepatol. 2026 Sep 2:S0168-8278(26)02876-X. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    
39. MOGA L, Payance A, Tellez L, Saltini D, et al
    Spleen stiffness measurement rules out high-risk varices in patients with chronic portal vein thrombosis without cirrhosis.
    J Hepatol. 2026 Sep 1:S0168-8278(26)02875-8. doi: 10.1016/j.jhep.2026.
    PubMed         Abstract available
    
    

    
    J Pediatr

40. ASAI A, Aqul A, Banc-Husu AM, Diamond T, et al
    Hepatotoxicity in AAV Gene Therapy: Clinical Challenges and Strategic Solutions.
    J Pediatr. 2026 Sep 4:115317. doi: 10.1016/j.jpeds.2026.115317.
    PubMed        
    
    

    
    Oncogene

41. VARADHARAJ V, Leon F, Krishna Kumar N, Nallasamy P, et al
    Distinct glycosyltransferase expression governs organ-specific survival in pancreatic cancer metastasis.
    Oncogene. 2026;45:3858-3873.
    PubMed         Abstract available
    
    

    
    PLoS One

42. YANG S, Liu H, Kou H, Lai L, et al
    Integrated computational analysis prioritizes candidate targets and pathways linking ochratoxin A exposure to hepatocellular carcinoma.
    PLoS One. 2026;21:e0357594.
    PubMed         Abstract available
    
    

    
    Radiology

43. AVRITSCHER R, Kim E, Chew V, Abou-Alfa GK, et al
    Convergence of Local and Systemic Therapies: A Comprehensive Society of Interventional Oncology Framework for (90)Y Radioembolization with Immunotherapy in HCC.
    Radiology. 2026;320:e251415.
    PubMed         Abstract available
    
    

    
    Transplant Proc

44. AQUINO RCM, Torres GG, Maciel RT, de Faria LJA, et al
    Multisystemic Anesthetic Management and Patient Blood Management in Urgent Liver Transplantation for Acute-on-Chronic Liver Failure: A Case Report.
    Transplant Proc. 2026 Jul 28:S0041-1345(26)00346.
    PubMed         Abstract available
    
    
45. ZANIN LYK, Duarte BKL, Maia ACA, de Liz CD, et al
    Liver Transplantation in a Patient With Fulminant Failure and Bone Marrow Aplasia Due to Methimazole: A Case Report.
    Transplant Proc. 2026 Jul 18:S0041-1345(26)00314.
    PubMed         Abstract available
    
    
46. PILZ M, Almeida P, Fernandes G, Souza A, et al
    Liver Transplantation for Metastatic Neuroendocrine Tumors: A Single-Center Experience in a Brazilian Referral Center.
    Transplant Proc. 2026 Jul 2:S0041-1345(26)00311.
    PubMed         Abstract available
    
    
47. GARCIA A, Teramoto FD, de Macedo PRA, Aguilar JMH, et al
    Liver Transplantation for Polycystic Liver Disease: A Retrospective Analysis From a University Center.
    Transplant Proc. 2026 Jun 17:S0041-1345(26)00244.
    PubMed         Abstract available
    
    
48. MENDONCA IC, Waisberg DR, Silva MS, Pinheiro RS, et al
    Treacherous Pitfalls in Liver Transplantation for Budd-Chiari Syndrome: When the Devil Hides in the Shadows-A Case Report.
    Transplant Proc. 2026 Jun 16:S0041-1345(26)00246.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Liver Diseases is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum